Needham Reiterates Buy on Conmed, Maintains $97 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson has reiterated a Buy rating on Conmed (NYSE:CNMD) and maintained a price target of $97.
October 31, 2024 | 11:22 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Mike Matson has reiterated a Buy rating on Conmed and maintained a price target of $97, indicating confidence in the company's stock performance.
The reiteration of a Buy rating and maintenance of a $97 price target by Needham suggests a positive outlook for Conmed's stock. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100